Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Dec 8;31(1):97-107.
doi: 10.1093/ajh/hpx138.

Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial

Carolyn H Still  1 , Carlos J Rodriguez  2 , Jackson T Wright Jr  3   4 , Timothy E Craven  5 , Adam P Bress  6 , Glenn M Chertow  7 , Paul K Whelton  8 , Jeffrey C Whittle  9 , Barry I Freedman  10 , Karen C Johnson  11 , Capri G Foy  12 , Jiang He  8 , John B Kostis  13 , James P Lash  14 , Carolyn F Pedley  15 , Roberto Pisoni  16 , James R Powell  17 , Barry M Wall  18 ; SPRINT Writing Group
Affiliations
Randomized Controlled Trial

Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial

Carolyn H Still et al. Am J Hypertens. .

Abstract

Background: The Systolic Blood Pressure Intervention Trial (SPRINT) showed that targeting a systolic blood pressure (SBP) of ≤ 120 mm Hg (intensive treatment) reduced cardiovascular disease (CVD) events compared to SBP of ≤ 140 mm Hg (standard treatment); however, it is unclear if this effect is similar in all racial/ethnic groups.

Methods: We analyzed SPRINT data within non-Hispanic White (NHW), non-Hispanic Black (NHB), and Hispanic subgroups to address this question. High-risk nondiabetic hypertensive patients (N = 9,361; 30% NHB; 11% Hispanic) 50 years and older were randomly assigned to intensive or standard treatment. Primary outcome was a composite of the first occurrence of a myocardial infarction, acute coronary syndrome, stroke, decompensated heart failure, or CVD death.

Results: Average postbaseline SBP was similar among NHW, NHB, and Hispanics in both treatment arms. Hazard ratios (HRs) (95% confidence interval) (intensive vs. standard treatment groups) for primary outcome were 0.70 (0.57-0.86), 0.71 (0.51-0.98), 0.62 (0.33-1.15) (interaction P value = 0.85) in NHW, NHB, and Hispanics. CVD mortality HRs were 0.49 (0.29-0.81), 0.77 (0.37-1.57), and 0.17 (0.01-1.08). All-cause mortality HRs were 0.61 (0.47-0.80), 0.92 (0.63-1.35), and 1.58 (0.73-3.62), respectively. A test for differences among racial/ethnic groups in the effect of treatment assignment on all-cause mortality was not significant (Hommel-adjusted P value = 0.062) after adjustment for multiple comparisons.

Conclusion: Targeting a SBP goal of ≤ 120 mm Hg compared to ≤ 140 mm Hg led to similar SBP control and was associated with similar benefits and risks among all racial ethnic groups, though NHBs required an average of ~0.3 more medications.

Clinical trials registration: Trial Number NCT01206062, ClinicalTrials.gov Identifier at https://clinicaltrials.gov/ct2/show/NCT01206062.

Keywords: African Americans; Hispanics; blood pressure; clinical outcomes; clinical trials; hypertension; race and ethnicity.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Consort diagram. Race/ethnicity was self-reported and participants were classified as: Hispanic regardless of self-identified race; non-Hispanic Black if self-identified as African American alone; and non-Hispanic White if self-identified as White alone.
Figure 2.
Figure 2.
Follow-up SBP and mean number of antihypertensive meds by treatment arm and race/ethnicity. The SBP separation between treatment groups at year 12, 24, and 36 months was 14.4, 15.6, and 16.7 mm Hg, respectively in NHBs; 14.8, 15.5, and 15.0.
See this image and copyright information in PMC

References

    1. Whelton PK, Einhorn PT, Muntner P, Appel LJ, Cushman WC, Diez Roux AV, Ferdinand KC, Rahman M, Taylor HA, Ard J, Arnett DK, Carter BL, Davis BR, Freedman BI, Cooper LA, Cooper R, Desvigne-Nickens P, Gavini N, Go AS, Hyman DJ, Kimmel PL, Margolis KL, Miller ER, 3rd, Mills KT, Mensah GA, Navar AM, Ogedegbe G, Rakotz MK, Thomas G, Tobin JN, Wright JT, Yoon SS, Cutler JA; National Heart, Lung, and Blood Institute Working Group on Research Needs to Improve Hypertension Treatment and Control in African Americans Research needs to improve hypertension treatment and control in African Americans. Hypertension 2016; 68:1066–1072. - PMC - PubMed
    1. Borrell LN, Crawford ND. Disparities in self-reported hypertension in Hispanic subgroups, non-Hispanic Black and non-Hispanic White adults: the National Health Interview Survey. Ann Epidemiol 2008; 18:803–812. - PMC - PubMed
    1. Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension 2011; 57:1101–1107. - PMC - PubMed
    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee; Stroke Statistics Subcommittee Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016; 133:e38–360. - PubMed
    1. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the united states: National Health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief 2013; 1–8. - PubMed

Publication types

MeSH terms

Substances

Associated data